Evidence map›Paper›PMID 40872522›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

Repurposing Diabetes Therapies in CKD: Mechanistic Insights, Clinical Outcomes and Safety of SGLT2i and GLP-1 RAs.

Syed Arman Rabbani, Mohamed El-Tanani, Rakesh Kumar, Manita Saini, Yahia El-Tanani, Shrestha Sharma, Alaa A A Aljabali, Eman Hajeer, Manfredi Rizzo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Syed Arman RabbaniRAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.ORCID 0000-0002-8454-8158
Mohamed El-TananiRAK College of Pharmacy, RAK Medical and Health Sciences University, Ras Al Khaimah 11172, United Arab Emirates.
Rakesh KumarAmity Institute of Pharmacy, Amity University, Gurgaon 122413, Haryana, India.
Manita SainiAmity Institute of Pharmacy, Amity University, Gurgaon 122413, Haryana, India.
Yahia El-TananiRoyal Cornwall Hospital, NHS Trust, Truro TR1 3LJ, UK.
Shrestha SharmaAmity Institute of Pharmacy, Amity University, Gurgaon 122413, Haryana, India.
Alaa A A AljabaliDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.ORCID 0000-0002-9519-6338
Eman HajeerFaculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK.ORCID 0009-0008-0164-8753
Manfredi RizzoDepartment of Health Promotion, Mother and Childcare, Internal Medicine and Medical Specialties, School of Medicine, University of Palermo, 90127 Palermo, Italy.ORCID 0000-0002-9549-8504

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

(CKD) Chronic Kidney Disease(DKD) Diabetic Kidney DiseaseGLP-1 RAsSGLT2i

Identifiers

PMID40872522
PMCPMC12389137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.